Page 38 - Avoid Food and Drug Interactions

Commercially Available ILE in the US

Intralipid ®2,3 Nutrilipid®1 Clinolipid®2,3 Smoflipid®2,3 Omegaven®2,3
(Baxter)/ (Fresenius (Fresenius
(Baxter) * (B. Braun) Clinoleic® Kabi) Kabi)
100% fish oil
Lipid Source 100% soybean 100% soybean 20% soybean 30% soybean,
oil oil oil/80% olive oil 30% MCTs, 1:8
© 2019 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. 3.66 ± 0.59
25% olive oil,
15% fish oil 150–296

N-6:n-3 ratio 7:1 7:1 9:1 2.5:1 4.4
1.8
Phytosterols 342.89 ± 5.87- NA 226.83 ± 6.42- 178.54 ± 9.56-
(mcg/mL) 439.07 ± 5.72 274.38 ± 2.60 207

α-tocopherol 38 NA 327 + 8 200
(mg/L)

Linoleic 44-62 45-58 13.8-221 21.4
(% by weight) 0.5-4.21 2.5

α-Linolenic 4-11 4-11 71
(% by weight)

*Manufactured by Fresenius Kabi

Adapted from: 1. Mundi MS. Nutr Clin Pract. 2016;31:629-641
2. Vanek VW. Nutr Clin Pract. 2012;27(2):150-192
3. Vanke VW. Nutr Clin Pract. 2014;29(6):841

© 2019 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. Possible Risks with Soybean Oil (SO) ILE1

• Pro-inflammatory effects

o High n6:n3 ratio
o Decreased cell membrane fluidity and impact on lymphocyte function

• Negative effects on reticuloendothelial system (RES) clearance
• High phytosterol content
• Risk of liver dysfunction and progression of parenteral nutrition

associated liver disease (PNALD)

1. Mundi MS. Nutr Clin Pract. 2016;31:629-641

72

38